Skip to content
  • Biogen Idec and MAKScientific team up on MS drug candidates

    Mass High Tech - 03/14/2012

    MAKScientific, LLC, a privately held company in Boston focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.

  • Cookies on Northeastern sites

    This website uses cookies and similar technologies to understand your use of our website and give you a better experience. By continuing to use the site or closing this banner without changing your cookie settings, you agree to our use of cookies and other technologies. To find out more about our use of cookies and how to change your settings, please go to our Privacy Statement.